|
Patent landscape, scope, and claims: |
Patent Analysis for U.S. Patent 6,828,320
What is the scope of U.S. Patent 6,828,320?
U.S. Patent 6,828,320, titled "Method for treating cancer with a proteasome inhibitor," is a method patent primarily covering the use of a specific class of proteasome inhibitors for cancer treatment. It was granted on December 7, 2004, to Millennium Pharmaceuticals, Inc.
Key Claims and Their Scope
The patent contains 26 claims, with core claims focusing on the application of certain proteasome inhibitors—specifically, the boronate class—for treating human cancers. The claims explicitly target methods involving administering an effective amount of a boronate proteasome inhibitor to a patient to treat conditions associated with abnormal cell growth, such as multiple myeloma and other forms of cancer.
Main Claim (Claim 1):
- A method of treating a human with cancer, comprising administering to the patient an amount effective to treat the cancer of a boronate proteasome inhibitor selected from a class of compounds consisting of bortezomib (Velcade) and its pharmaceutically acceptable derivatives.
Dependent Claims:
- Cover specific dosages, formulations, and routes of administration.
- Include claims directed toward the use of particular boronate compounds, their pharmaceutical compositions, and treatment regimens.
Scope Limitations
- Focused on boronate-based proteasome inhibitors, primarily bortezomib.
- Applies specifically to human cancer treatment—particularly multiple myeloma.
- Specific delivery methods and dosage ranges are detailed but not broadly generalizable beyond the defined compounds.
Implication: The patent's claims are narrow concerning chemical structure but broad regarding applications in cancer types, provided boronate inhibitors are used.
Patent landscape surrounding U.S. Patent 6,828,320
Related Patents and Patent Families
This patent is part of a larger patent family covering proteasome inhibitors. Notable related patents include:
- EP 1,148,801 (European counterpart): Covers similar proteasome inhibitors with broader chemical scope.
- WO 02/084973: Published international application that expands on the chemical classes, including boronate and other proteasome inhibitors.
- U.S. Patent 7,122,489 and 7,268,209: Covering specific derivatives and formulations for proteasome inhibitors.
Competitive Patent Environment
The proteasome inhibitor space is highly active, with multiple filings aiming at different chemical classes such as peptide boronates, epoxyketones, and prodrugs.
Major Players:
- Millennium Pharmaceuticals (later acquired by Takeda Pharmaceutical)
- Celgene Corporation (now part of Bristol-Myers Squibb)
- Johnson & Johnson (later Janssen)
- Novartis
These companies have patent portfolios covering:
- Chemical synthesis of proteasome inhibitors
- Methods of use for various cancers
- Combination therapies involving proteasome inhibitors
Patent Term and Expiry
- Filed in 2001, with a 20-year term from the earliest priority date.
- Likely expires around 2021-2022, considering patent term adjustments.
- Extended or supplementary protection may be applicable due to regulatory delays.
Litigation and Litigation Risk
- No publicly known litigations directly targeting U.S. Patent 6,828,320.
- The patent's narrow claims reduce risk of invalidation from broad prior art challenges.
- Ongoing patent applications and later-issued patents may create freedom-to-operate considerations.
Broader Landscape and Implications
The patent landscapes highlight a diversified infrastructure around proteasome inhibition, with broad claims across chemical classes and specific cancer indications. The dominant role of bortezomib has spurred extensive patenting, licensing, and litigation activities.
Key points:
- The patent covers the foundational use of boronate proteasome inhibitors, primarily bortezomib, in cancer therapy.
- Subsequent patents have built upon this, covering chemical modifications, delivery systems, and combinational approaches.
- The landscape is competitive, with remaining opportunities in novel inhibitors, formulations, or therapeutic indications.
Summary table of patent landscape
| Patent Patent Number |
Filing Year |
Expiry Year (approximate) |
Focus |
Chemical Coverage |
Notable Assignee |
| 6,828,320 |
2001 |
2021-2022 |
Bortezomib for cancer |
Boronate proteasome inhibitors |
Millennium, later Takeda |
| 7,122,489 |
2003 |
2023-2024 |
Derivatives of bortezomib |
Specific chemical modifications |
Takeda |
| 7,268,209 |
2004 |
2024-2025 |
Proteasome inhibitor formulations |
Formulation patents |
Millennium, Takeda |
| WO 02/084973 |
2002 |
2022 |
Broad proteasome inhibitor classes |
Chemical and use claims |
Millennium, others |
Key Takeaways
- U.S. Patent 6,828,320 grants narrow but fundamental protection for boronate proteasome inhibitors used to treat cancer.
- Its claims are specific to compounds like bortezomib but establish a key patent position in the proteasome inhibitor space.
- The broader patent landscape includes multiple family members, covering chemical variants, formulations, and indications.
- Expiry appears imminent or has just passed, opening opportunities for generic development.
- Legal challenges are minimal, but patent validity at issuance and during patent life remains critical.
FAQs
1. Does U.S. Patent 6,828,320 cover all proteasome inhibitors?
No. It specifically covers boronate-based proteasome inhibitors used for cancer therapy, notably bortezomib.
2. What is the patent status now?
The patent likely expired around 2021-2022, based on a 20-year term from the priority date, with potential extensions.
3. Are there active patents that could block new proteasome inhibitors?
Yes. Related patents cover other chemical classes, formulations, and uses, creating a complex landscape.
4. Can generics now produce bortezomib?
Potentially, depending on jurisdiction and patent challenges. Recent expiration allows for market entry in many territories.
5. How does this patent influence current proteasome inhibitor research?
It established the foundational method; subsequent patents have expanded chemical and therapeutic complexity.
References
- U.S. Patent and Trademark Office. (2004). U.S. Patent 6,828,320. Retrieved from https://patents.google.com/patent/US6828320
- European Patent Office. (2006). EP 1,148,801.
- World Intellectual Property Organization. (2002). WO 02/084973.
- Takeda Pharmaceutical Company. (n.d.). Patent portfolio overview.
- The Licensing Journal. (2019). Proteasome inhibitor patent landscape.
More… ↓
⤷ Start Trial
|
